AR091090A1 - Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas - Google Patents

Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas

Info

Publication number
AR091090A1
AR091090A1 ARP130101729A ARP130101729A AR091090A1 AR 091090 A1 AR091090 A1 AR 091090A1 AR P130101729 A ARP130101729 A AR P130101729A AR P130101729 A ARP130101729 A AR P130101729A AR 091090 A1 AR091090 A1 AR 091090A1
Authority
AR
Argentina
Prior art keywords
small cell
treatment
human patient
nucleotides
metastatic
Prior art date
Application number
ARP130101729A
Other languages
English (en)
Spanish (es)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR091090A1 publication Critical patent/AR091090A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP130101729A 2012-05-18 2013-05-17 Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas AR091090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
AR091090A1 true AR091090A1 (es) 2014-12-30

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101729A AR091090A1 (es) 2012-05-18 2013-05-17 Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100820266B1 (ko) 1999-02-26 2008-04-08 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2011253253B2 (en) 2010-05-08 2015-10-22 Bruin Biometrics, Llc SEM scanner sensing apparatus, system and methodology for early detection of ulcers
WO2012123823A1 (en) 2011-03-15 2012-09-20 The University Of British Columbia Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA2982249C (en) 2015-04-24 2019-12-31 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
CN109890282A (zh) 2017-02-03 2019-06-14 布鲁恩生物有限责任公司 糖尿病足溃疡易感性的测量
GB2569922B (en) 2017-02-03 2022-02-02 Bruin Biometrics Llc Measurement of edema
NZ796503A (en) 2017-02-03 2025-08-29 Bbi Medical Innovations Llc Measurement of tissue viability
KR20200111671A (ko) 2017-11-16 2020-09-29 브루인 바이오메트릭스, 엘엘씨 표피하 수분값을 이용한 압박성 궤양의 전략적 치료법
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
CA3090395A1 (en) 2018-02-09 2019-08-15 Bruin Biometrics, Llc Detection of tissue damage
FI4283799T3 (fi) 2018-10-11 2025-04-23 Bruin Biometrics Llc Kertakäyttöisellä elementillä varustettu laite
MX2023009108A (es) 2021-02-03 2023-08-09 Bruin Biometrics Llc Métodos de tratamiento de daño tisular inducido por presión en estadio profundo y temprano.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
MX2010014228A (es) * 2008-06-18 2011-03-29 Abbott Laboratories Star Metodos y productos de diagnostico del p/gf-1 acompañante.
SG194931A1 (en) * 2011-05-19 2013-12-30 Teva Pharma Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
PH12014502569A1 (en) 2015-01-21
JP2015522542A (ja) 2015-08-06
KR20150024843A (ko) 2015-03-09
EA201492148A1 (ru) 2015-04-30
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30
CA2874092A1 (en) 2013-11-21
AU2013262589A1 (en) 2015-01-22
IN2014DN10390A (enExample) 2015-08-14
TW201402132A (zh) 2014-01-16
UY34812A (es) 2013-12-31
IL235459A0 (en) 2014-12-31
EP2849761A1 (en) 2015-03-25
CN104684564A (zh) 2015-06-03
WO2013173757A8 (en) 2015-04-30
BR112014028787A2 (pt) 2017-06-27
US20130310440A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
AR091090A1 (es) Metodo para el tratamiento del cancer de pulmon de celulas no pequeñas
Kim et al. MicroRNA targeting by quercetin in cancer treatment and chemoprotection
MX2013013384A (es) Metodo para tratamiento de cancer de pulmon de celulas no pequeñas.
WO2013086444A3 (en) Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
EP3800255A3 (en) Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
NZ700759A (en) Combination therapy for treating cancer
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
MX359548B (es) Agentes de iarn modificados.
EP4483965A3 (en) Individualized vaccines for cancer
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
WO2011091390A3 (en) Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
EA201590070A1 (ru) ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
Wang et al. The regulatory roles of miRNA and methylation on oncogene and tumor suppressor gene expression in pancreatic cancer cells
MX2019005101A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
EA201791471A1 (ru) Способы применения антисмысловых олигонуклеотидов smad7
SG10201806064XA (en) Anti-tumor compositions and methods
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
AR083445A1 (es) siARN CONTRA LA FIBROSIS
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
AR095416A1 (es) Tratamiento con cutirsen que presenta una toxicidad reducida

Legal Events

Date Code Title Description
FB Suspension of granting procedure